{"id":"paliperidone-er-oros","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Weight gain"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL2107360","moleculeType":"Small molecule","molecularWeight":"664.91"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking dopamine receptors, Paliperidone ER OROS reduces the symptoms of schizophrenia and schizoaffective disorder. It is a long-acting formulation of paliperidone, which is released slowly over time to maintain therapeutic levels in the bloodstream.","oneSentence":"Paliperidone ER OROS is an atypical antipsychotic that works by blocking dopamine receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:24.866Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Schizoaffective disorder"}]},"trialDetails":[{"nctId":"NCT00396565","phase":"PHASE3","title":"A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2006-07","conditions":"Schizophrenia","enrollment":394},{"nctId":"NCT00791401","phase":"PHASE1","title":"A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-04","conditions":"Schizophrenia, Renal Impairment","enrollment":47},{"nctId":"NCT00791232","phase":"PHASE1","title":"A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-03","conditions":"Schizophrenia","enrollment":113},{"nctId":"NCT00892489","phase":"PHASE1","title":"A Bioequivalence Study of 15 mg ER OROS Paliperidone","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT00796276","phase":"PHASE1","title":"A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-05","conditions":"Schizophrenia","enrollment":20},{"nctId":"NCT00796081","phase":"PHASE1","title":"A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-01","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders","enrollment":25},{"nctId":"NCT00796185","phase":"PHASE1","title":"As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":62},{"nctId":"NCT00892320","phase":"PHASE1","title":"A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-03","conditions":"Schizophrenia","enrollment":20},{"nctId":"NCT00892541","phase":"PHASE1","title":"A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-10","conditions":"Schizophrenia","enrollment":30},{"nctId":"NCT00650793","phase":"PHASE3","title":"A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-03","conditions":"Schizophrenia","enrollment":473},{"nctId":"NCT00645307","phase":"PHASE3","title":"A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-05","conditions":"Schizophrenia","enrollment":235},{"nctId":"NCT00758030","phase":"PHASE1","title":"Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-03","conditions":"Schizophrenia","enrollment":60},{"nctId":"NCT00752427","phase":"PHASE3","title":"24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-06","conditions":"Schizophrenia","enrollment":86},{"nctId":"NCT00796835","phase":"PHASE1","title":"A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":50},{"nctId":"NCT00350467","phase":"PHASE3","title":"A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2006-06","conditions":"Acute Schizophrenia","enrollment":288},{"nctId":"NCT00210769","phase":"PHASE3","title":"A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-01","conditions":"Schizophrenia","enrollment":203},{"nctId":"NCT00838669","phase":"PHASE1","title":"A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2005-08","conditions":"Schizophrenia","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Paliperidone ER OROS","genericName":"Paliperidone ER OROS","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paliperidone ER OROS is a small molecule that acts as a dopamine D2 receptor antagonist, classified as an antagonist. It is used to treat conditions such as schizophrenia and schizoaffective disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}